Efficacy and safety of semaglutide 1.0 mg once-weekly versus liraglutide 1.2 mg once-daily as add-on to 1-3 oral anti-diabetic drugs (OADs) in subjects with type 2 diabetes
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 18 Jan 2018
At a glance
- Drugs Semaglutide (Primary) ; Liraglutide
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms SUSTAIN 10
- Sponsors Novo Nordisk
- 14 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 28 Jun 2017 Planned End Date changed from 12 Aug 2018 to 14 Aug 2018.
- 28 Jun 2017 Status changed from not yet recruiting to recruiting.